Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis

Table 1 Demographics and clinical characteristics of the study participants

Category		Grade 4 glioma		p-value
		IDH1 mutant (IDH1-Mut astrocytoma)	IDH1 wild type (GBM)
		n = 10	n = 51
Age at Diagnosis (yrs)	Mean (sd)	59.5 (12)	39.3 (7)
	Median (lq,uq)	61.0 (54.5,67.0)	38.0 (34,42.8)	0.00^a
	No. < 40 yrs	5 (50.0%)	7 (13.7%)
Sex	Female	3 (30.0%)	20 (39.2%)	0.85^b
Sex	Male	7 (70.0%)	31 (60.8%)	0.85^b
Population	African American	1 (10.0%)	1 (2.0%)
	European American	8 (80.0%)	32 (62.7%)	0.34^b
	Multiracial	–	5 (9.8%)
	Unknown	1 (10.0%)	12 (23.5%)
Molecular Subtype^c	Classical	1 (10.0%)	16 (31.4%)
	Mesenchymal	2 (20.0%)	19 (37.3%)	0.03^b
	Neural	–	4 (7.8%)
	Proneural	7 (70.0%)	12 (23.5%)
Pre-Treatment	Treatment Naïve	4 (40.0%)	35 (68.6%)
	RT	6 (60.0%)	11 (21.6%)	0.08^b
	TMZ	6 (60.0%)	12 (23.5%)
Post-Treatment	Treatment Naïve	2 (20.0%)	12 (23.5%)
	RT	6 (60.0%)	35 (68.6%)	1^b
	TMZ	8 (80.0%)	34 (66.7%)
Recurrence Status	Newly-diagnosed	4 (40%)	35 (68.6%)	0.17^b
Recurrence Status	Recurrent	6 (60%)	16 (31.4%)
Survival Status	Alive	6 (60.0%)	16 (31.4%)	0.17^b
Survival Status	Dead	4 (40.0%)	35 (68.6%)
Overall Survival (months)	Alive—mean (sd)	36.0 (9.6)	18.0 (13.2)
Overall Survival (months)	Dead—mean (sd)	15.6 (15.6)	10.2 (8.4)

IDH1 isocitrate dehydrogenase 1, RT radio therapy, TMZ temozolomide chemotherapy, sd standard deviation, lq lower quantile, uq upper quantile
^aTwo-tailed Wilcoxon rank sum test
^bPearson's Chi-squared test for two-sample proportions
^cSubtypes predicted based on the expression profiles of core gene signatures

ISSN: 2051-5960